Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

Diabetologia

Volumn 54, Issue 2, 2011, Pages 280-290

  Davis, T M E ^a   Ting, R ^b,e   Best, J D ^c   Donoghoe, M W ^b   Drury, P L ^d   Sullivan, D R ^e   Jenkins, A J ^c   O'Connell, R L ^b   Whiting, M J ^f   Glasziou, P P ^g   Simes, R J ^b   Kesaniemi Y A ^h,i   Gebski, V J ^b   Scott, R S ^j   Keech, A C ^b,e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d GREEN LANE HOSPITAL   (New Zealand)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f FLINDERS MEDICAL CENTRE   (Australia)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF OULU   (Finland)

ⁱ OULU UNIVERSITY HOSPITAL   (Finland)

^j CHRISTCHURCH HOSPITAL   (New Zealand)

more..

Author keywords

Albuminuria; Creatinine; Diabetes; Fenofibrate; FIELD; GFR; Nephropathy; Renal impairment

Indexed keywords

ALBUMIN; CREATININE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMINURIA; ARTICLE; CREATININE BLOOD LEVEL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; REMISSION;

AGED; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; FENOFIBRATE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED;

EID: 78951474167     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1951-1     Document Type: Article

References (45)

1. The FIELD Study Investigators 2005 Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial Lancet 366 1849 1861 10.1016/S0140-6736(05)67667-2
2. The ACCORD Study Group 2010 Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 1563 1574 10.1056/NEJMoa1001282
3. The ACCORD Study Group and ACCORD Eye Study Group 2010 Effects of medical therapies on retinopathy progression in type 2 diabetes N Engl J Med 363 233 244 10.1056/NEJMoa1001288
4. AC Keech P Mitchell PA Summanen, et al. 2007 Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD Study): a randomised controlled trial Lancet 370 1687 1697 1:CAS:528:DC%2BD2sXhtlWrsb7K 10.1016/S0140-6736(07)61607-9 17988728
5. K Rajamani PG Colman LP Li, et al. 2009 Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD Study): a prespecified analysis of a randomised controlled trial Lancet 373 1780 1788 1:CAS:528:DC%2BD1MXmtlektr8%3D 10.1016/S0140-6736(09)60698-X 19465233
6. American Diabetes Association 2003 Diabetic nephropathy. Position statement Diabetes Care 26 S94 S98 10.2337/diacare.26.7.2194
7. H Kastarinen O Ukkola YA Kesaniemi 2009 Glomerular filtration rate is related to carotid intima-media thickness in middle-aged adults Nephrol Dial Transplant 24 2767 2772 10.1093/ndt/gfp172 19369688
8. ME Cooper K Jandeleit-Dahm MC Thomas 2005 Targets to retard the progression of diabetic nephropathy Kidney Int 68 1439 1445 10.1111/j.1523-1755. 2005.00555.x 16164619
9. Drury P, Ting R, Zannino D, et al. (2010) Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia. doi: 10.1007/s00125-010-1854-1
10. CW Park Y Zhang X Zhang, et al. 2006 PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice Kidney Int 69 1511 1517 1:CAS:528:DC%2BD28XjvF2lu7c%3D 10.1038/sj.ki.5000209 16672921
11. J-C Ansquer C Foucher S Rattier M-R Taskinen G Steiner 2005 Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am J Kidney Dis 45 485 493 1:CAS:528:DC%2BD2MXislOjsbk%3D 10.1053/j.ajkd.2004.11.004 15754270
12. AS Levey JP Bosch JB Lewis T Greene N Rogers D Roth 1999 A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Ann Intern Med 130 461 470 1:CAS:528:DyaK1MXitFChs7k%3D 10075613
13. RA Chudleigh G Dunseath W Evans, et al. 2007 How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes? Diab Care 30 300 305 10.2337/dc06-1688
14. United States Renal Data System 2009 ADR Atlas (2009) Available from www.usrds.org, accessed 20 December 2009
15. P Gaede H Lund-Andersen H-H Parving O Pedersen 2008 Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580 591 1:CAS:528:DC%2BD1cXhs1entLc%3D 10.1056/NEJMoa0706245 18256393
16. J-C Ansquer RN Dalton E Causse D Crimet KL Malicot C Foucher 2008 Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people Am J Kidney Dis 51 904 913 1:CAS:528:DC%2BD1cXotV2hsbw%3D 10.1053/j.ajkd.2008.01.014 18501783
17. JW Rowe R Anderes JD Tobin AH Norris NW Shock 1976 The effect of age on creatinine clearance in men: a cross-sectional and longtitudinal study J Gerontol 31 155 163 1:CAS:528:DyaE28XktlWjsbs%3D 1249404
18. HL Heerspink D de Zeeuw 2010 Composite renal endpoints: was ACCOMPLISH accomplished? Lancet 375 1140 1142 10.1016/S0140-6736(10)60098-0 20170949
19. GL Bakris PA Sarafidis MR Weir, et al. 2010 Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial Lancet 375 1173 1181 1:CAS:528:DC%2BC3cXktlGitr8%3D 10.1016/S0140-6736(09)62100-0 20170948
20. S Klahr AS Levey GJ Beck, et al. 1994 The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease N Engl J Med 330 877 884 1:STN:280:DyaK2c7lvFSisg%3D%3D 10.1056/NEJM199403313301301 8114857
21. C Forsblom A Hiukka E Leinonen J Sundvall PH Groop M-R Taskinen 2010 Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: FIELD Helsinki Substudy Diab Care 33 215 220 1:CAS:528: DC%2BC3cXitlalsLY%3D 10.2337/dc09-0621
22. P Sjöström M Tidman I Jones 2005 Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans Scand J Clin Lab Invest 65 111 124 10.1080/00365510510013523 16025834
23. EL Knight JC Verhave D Spiegelman, et al. 2004 Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement Kidney Int 65 1416 1421 1:CAS:528:DC%2BD2cXjtF2js7w%3D 10.1111/j.1523-1755.2004.00517.x 15086483
24. C Hottelart NE Esper JM Achard A Pruna A Fournier 1999 Fenofibrate increases blood creatinine, but does not change the glomerular filtration rate in patients with mild renal insufficiency Néphrologie 20 41 44 1:STN:280:DyaK1M7otVyktA%3D%3D 10081035
25. C Hottelart NE Esper F Rose J-M Achard A Fournier 2002 Fenofibrate increases creatinemia by increasing metabolic production of creatinine Nephron 92 536 541 1:CAS:528:DC%2BD38XnslWqtrY%3D 10.1159/000064083 12372935
26. MW Taal BM Brenner 2000 Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists Kidney Int 57 1803 1817 1:CAS:528: DC%2BD3cXjsFCiu7s%3D 10.1046/j.1523-1755.2000.00031.x 10792600
27. GL Bakris MR Weir 2000 Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch Intern Med 160 685 693 1:CAS:528:DC%2BD3cXit1Smtr4%3D 10.1001/archinte.160.5.685 10724055
28. R Collins J Armitage S Parish P Sleight R Peto for the Heart Protection Study Collaborative Group 2003 MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2005 2016 10.1016/S0140-6736(03)12475-0 12814710
29. HM Colhoun DJ Betteridge PN Durrington, et al. 2009 Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) Am J Kidney Dis 54 810 819 1:CAS:528:DC%2BD1MXhsFahs77I 10.1053/j.ajkd.2009.03. 022 19540640
30. J Shepherd JJP Kastelein V Bittner, et al. 2007 Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) Study Clin J Am Soc Nephrol 2 1131 1139 1:CAS:528:DC%2BD2sXhtlGgsbnE 10.2215/CJN.04371206 17942759
31. SH Han MJ Quon KK Koh 2005 Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-[alpha] activators Hypertension 46 1086 1092 1:CAS:528:DC%2BD2MXhtFCisbnJ 10.1161/01.HYP.0000187900.36455.4c 16230515
32. Y Anami S Kobori M Sakai, et al. 1997 Human beta-migrating very low density lipoprotein induces foam cell formation in human mesangial cells Atherosclerosis 135 225 234 1:CAS:528:DyaK2sXntVOisrY%3D 10.1016/S0021-9150(97) 00166-4 9430372
33. R Olufadi CD Byrne 2006 Effects of VLDL and remnant particles on platelets Pathophysiol Haemost Thromb 35 281 291 1:CAS:528:DC%2BD28XnsFCktbY%3D 10.1159/000093221 16877877
34. GX Shen 2003 Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells Mol Cell Biochem 246 69 74 1:CAS:528:DC%2BD3sXjtFKmt7o%3D 10.1023/A:1023455912456 12841345
35. P Muntner J Coresh JC Smith J Eckfeldt MJ Klag 2000 Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities Study Kidney Int 58 293 301 1:CAS:528:DC%2BD3cXltVyjtbg%3D 10.1046/j.1523-1755. 2000.00165.x 10886574
36. MF Lopes-Virella RE Carter GE Gilbert, et al. 2008 Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications Diab Care 31 2006 2012 1:CAS:528:DC%2BD1cXht1KksLfL 10.2337/dc08-0659
37. PJ Barter S Nicholls K Rye GM Anantharamaiah M Navab AM Fogelman 2004 Antiinflammatory properties of HDL Circ Res 95 764 772 1:CAS:528: DC%2BD2cXot1aitrY%3D 10.1161/01.RES.0000146094.59640.13 15486323
38. V Agrawal A Shah C Rice BA Franklin PA McCullough 2009 Impact of treating the metabolic syndrome on chronic kidney disease Nat Rev Nephrol 5 520 528 1:CAS:528:DC%2BD1MXhtVGrsb3O 10.1038/nrneph.2009.114 19636332
39. H-H Parving H Lehnert J Brochner-Mortensen, et al. 2001 The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 870 878 1:CAS:528:DC%2BD3MXntlelsLY%3D 10.1056/NEJMoa011489 11565519
40. R Retnakaran CA Cull KI Thorne AI Adler RR Holman for the UKPDS Study Group 2006 Risk factors for renal dysfunction in type 2 diabetes. UKPDS 74 Diabetes 55 1832 1839 1:CAS:528:DC%2BD28Xlsl2gu7w%3D 10.2337/db05-1620 16731850
41. HC Gerstein S Yusuf JFE Mann, et al. 2000 Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE Substudy Lancet 355 253 259 1:CAS:528:DC%2BD3cXhtlCgsbg%3D 10.1016/S0140-6736(05)72261-3
42. WA Davis MW Knuiman TME Davis 2010 An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study Intern Med J 40 286 292 1:CAS:528:DC%2BC3cXntVyiu7g%3D 10.1111/j.1445-5994.2009.01958.x 19323700
43. JG Toffaletti EH McDonnell 2008 Variation of serum creatinine, cystatin C, and creatinine clearance tests in persons with normal renal function Clin Chim Acta 395 115 119 1:CAS:528:DC%2BD1cXptVCns74%3D 10.1016/j.cca.2008.05.020 18573244
44. AS Levey LA Stevens CH Schmid, et al. 2009 A new equation to estimate glomerular filtration Rate Ann Intern Med 150 604 612 19414839
45. J Warram G Gearin L Laffel A Krolewski 1996 Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio J Am Soc Nephrol 7 930 937 1:STN:280: DyaK28zosF2ksQ%3D%3D 8793803